Fig. 1

Identification of protein biomarker candidates using discovery proteomics. A Graphical abstract of the patient groups and number of samples included in the discovery phase. B Overview of the proteomics workflow used in the discovery phase. HGSC indicates high-grade serous ovarian cancer tumours. C Volcano plots of the pairwise comparisons between the three groups included in the discovery phase (chemoresistant with TFIp < 6 months, chemosensitive with TFIp > 6 months and chemosensitive with no recurrence). Highlighted in red are the differentially expressed proteins and highlighted in blue are the proteins present in at least four patients in one group and completely absent in the other group